In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast  to explore the unique challenges and innovative solutions reshaping market access and pricing within rare disease.  

Isabel shares insights from her extensive experience with due diligence assessments in orphan drug development, discussing three transformative strategies that are revolutionising how companies prove value in ultra-rare diseases. From multi-domain endpoints and visual evidence to payment-by-results models, this episode reveals why traditional HTA frameworks fall short for orphan drugs and how early collaboration between pricing, market access, and clinical teams is essential for success. 

Isabel has authored a blog on this topic, which you can read here: accessinfinity.com/blogs/breaking-through-barriers-how-innovation-is-revolutionising-orphan-drug-development. 

Send us Fan Mail

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör Access Infinity. Innehållet i podden är skapat av Access Infinity och inte av, eller tillsammans med, Poddtoppen.